{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:16:30Z","timestamp":1778523390450,"version":"3.51.4"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002790","name":"Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["1459"],"award-info":[{"award-number":["1459"]}],"id":[{"id":"10.13039\/501100002790","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    Congestive heart failure, a prominent cardiovascular disease results primarily from myocardial infarction or ischemia. Milrinone (MRN), a widely used clinical drug for heart failure, improves myocardial contractility and cardiac function through its inotropic and vasodilatory effects. However, lacking target specificity, it exhibits low bioavailability and lower body retention time. Therefore, in this study, angiotensin II (AT1) peptide conjugated human serum albumin nanoparticles (AT1-HSA-MRN-NPs) have been synthesized for targeted delivery of MRN to the myocardium, overexpressing AT1 receptors under heart failure. The NPs were surface functionalized through a covalent conjugation reaction between HSA and AT1. Nanoparticle size was 215.2\u00b14.7 nm and zeta potential -28.8\u00b12.7 mV and cumulative release of MRN was ~72% over 24 hrs. The intracellular uptake of nanoparticles and cell viability was studied in H9c2 cells treated with AT1-MRN-HSA-NPs vs the control non-targeted drug, MRN Lactate under normal, hypoxic and hypertrophic conditions. The uptake of AT1-HSA-MRN-NPs in H9c2 cells was significantly higher as compared to non-targeted nanoparticles, and the viability of H9c2 cells treated with AT1-MRN-HSA-NPs vs MRN Lactate was 73.4\u00b11.4% vs 44.9\u00b11.4%, respectively. Therefore, AT1-HSA-MRN-NPs are safe for\n                    <jats:italic>in vivo<\/jats:italic>\n                    use and exhibit superior targeting and drug delivery characteristics for treatment of heart failure.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0254305","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T14:11:29Z","timestamp":1633011089000},"page":"e0254305","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Synthesis and characterization of peptide conjugated human serum albumin nanoparticles for targeted cardiac uptake and drug delivery"],"prefix":"10.1371","volume":"16","author":[{"given":"Nikita","family":"Lomis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Westfall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Shum-Tim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4902-2353","authenticated-orcid":true,"given":"Satya","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"issue":"12","key":"pone.0254305.ref001","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics\u20142018 update: a report from the American Heart Association","volume":"137","author":"E.J. Benjamin","year":"2018","journal-title":"Circulation"},{"issue":"7","key":"pone.0254305.ref002","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/jcm5070062","article-title":"Heart Failure: Diagnosis, Management and Utilization","volume":"5","author":"A.A. Inamdar","year":"2016","journal-title":"Journal of clinical medicine"},{"issue":"8","key":"pone.0254305.ref003","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jacc.2018.11.053","article-title":"PCI and CABG for Treating Stable Coronary Artery Disease: JACC Review Topic of the Week","volume":"73","author":"T. Doenst","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"pone.0254305.ref004","first-page":"161","article-title":"Survival following a diagnosis of heart failure in primary care","volume":"34","author":"C.J. Taylor","year":"2017","journal-title":"Family practice"},{"issue":"10","key":"pone.0254305.ref005","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.1021\/nl2025882","article-title":"Nanoparticles targeting the infarcted heart","volume":"11","author":"T. Dvir","year":"2011","journal-title":"Nano letters"},{"key":"pone.0254305.ref006","article-title":"Overexpression of type I angiotensin II receptors impairs excitation-contraction coupling in the mouse heart","author":"K. Rivard","year":"2011","journal-title":"American Journal of Physiology-Heart and Circulatory Physiology"},{"issue":"2","key":"pone.0254305.ref007","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1073\/pnas.97.2.931","article-title":"Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling","volume":"97","author":"P. Paradis","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"pone.0254305.ref008","article-title":"Role of cardiac overexpression of angiotensin II in the regulation of cardiac function and remodeling post-myocardial infarction","author":"J. Xu","year":"2007","journal-title":"American Journal of Physiology-Heart and Circulatory Physiology"},{"issue":"1","key":"pone.0254305.ref009","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12872-017-0686-z","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials","volume":"17","author":"C. Tai","year":"2017","journal-title":"BMC cardiovascular disorders"},{"issue":"8","key":"pone.0254305.ref010","doi-asserted-by":"crossref","first-page":"e003956","DOI":"10.1161\/CIRCHEARTFAILURE.117.003956","article-title":"Dose of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and outcomes in heart failure: a meta-analysis. Circulation","volume":"10","author":"M.S. Khan","year":"2017","journal-title":"Heart Failure"},{"issue":"7\u20138","key":"pone.0254305.ref011","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3109\/1061186X.2015.1035276","article-title":"Multivalent targeting of AT1 receptors with angiotensin II-functionalized nanoparticles","volume":"23","author":"R. Hennig","year":"2015","journal-title":"J Drug Target"},{"issue":"7","key":"pone.0254305.ref012","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1021\/acs.molpharmaceut.7b00360","article-title":"Novel Milrinone Nanoformulation for Use in Cardiovascular Diseases: Preparation and in Vitro Characterization","volume":"15","author":"N. Lomis","year":"2017","journal-title":"Molecular pharmaceutics"},{"issue":"6","key":"pone.0254305.ref013","first-page":"203","article-title":"Phosphodiesterase inhibitors and the cardiovascular system. Continuing Education in Anaesthesia, Critical Care &","volume":"7","author":"R. Feneck","year":"2007","journal-title":"Pain"},{"issue":"3 Pt 2","key":"pone.0254305.ref014","first-page":"III10","article-title":"Pharmacology of the bipyridines: amrinone and milrinone","volume":"73","author":"A. Alousi","year":"1986","journal-title":"Circulation"},{"issue":"13","key":"pone.0254305.ref015","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJM198309293091302","article-title":"Evaluation of a new bipyridine inotropic agent\u2014milrinone\u2014in patients with severe congestive heart failure","volume":"309","author":"D.S. Baim","year":"1983","journal-title":"New England journal of medicine"},{"issue":"5","key":"pone.0254305.ref016","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1378\/chest.109.5.1302","article-title":"Hemodynamic effects of iv milrinone lactate in pediatric patients with septic shock: A prospective, double-blinded, randomized, placebo-controlled, interventional study","volume":"109","author":"P. Barton","year":"1996","journal-title":"CHEST Journal"},{"issue":"11","key":"pone.0254305.ref017","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40261-015-0325-3","article-title":"Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis: a prospective, randomized trial","volume":"35","author":"Z. Wang","year":"2015","journal-title":"Clinical drug investigation"},{"issue":"4","key":"pone.0254305.ref018","first-page":"261","article-title":"ACE-inhibitors, Beta-blockers or the Combination in Heart Failure: Is It Just an A\u2013B\u2013C?","volume":"22","author":"R.A. de Boer","year":"2008","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"12","key":"pone.0254305.ref019","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","article-title":"Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial","volume":"287","author":"M.S. Cuffe","year":"2002","journal-title":"Jama"},{"key":"pone.0254305.ref020","article-title":"Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: preparation and in vitro assessment","author":"S. Abbasi","year":"2012","journal-title":"Journal of drug delivery, 2011"},{"key":"pone.0254305.ref021","first-page":"525","article-title":"Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis","volume":"5","author":"S. Sebak","year":"2010","journal-title":"International journal of nanomedicine"},{"issue":"6","key":"pone.0254305.ref022","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/nano6060116","article-title":"Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization","volume":"6","author":"N. Lomis","year":"2016","journal-title":"Nanomaterials"},{"issue":"7","key":"pone.0254305.ref023","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1021\/acs.molpharmaceut.7b00360","article-title":"Novel Milrinone Nanoformulation for Use in Cardiovascular Diseases: Preparation and in Vitro Characterization","volume":"15","author":"N. Lomis","year":"2018","journal-title":"Mol Pharm"},{"issue":"2","key":"pone.0254305.ref024","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/2230-973X.82432","article-title":"Preparation and characterization of albumin nanoparticles encapsulating curcumin intended for the treatment of breast cancer","volume":"1","author":"A. Jithan","year":"2011","journal-title":"International journal of pharmaceutical investigation"},{"key":"pone.0254305.ref025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.msec.2017.02.018","article-title":"A new bioavailability enhancement strategy of curcumin via self-assembly nano-complexation of curcumin and bovine serum albumin","volume":"C75","author":"H. Yu","year":"2017","journal-title":"Materials Science and Engineering"},{"issue":"4","key":"pone.0254305.ref026","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4161\/cbt.13.4.18692","article-title":"RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy","volume":"13","author":"S. Ji","year":"2012","journal-title":"Cancer biology & therapy"},{"key":"pone.0254305.ref027","doi-asserted-by":"crossref","first-page":"31539","DOI":"10.1038\/srep31539","article-title":"Enhanced tumor targeting of cRGD peptide-conjugated albumin nanoparticles in the BxPC-3 cell line","author":"X. Yu","year":"2016","journal-title":"Scientific reports"},{"issue":"9","key":"pone.0254305.ref028","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1021\/acs.molpharmaceut.5b00153","article-title":"Ligand-modified human serum albumin nanoparticles for enhanced gene delivery","volume":"12","author":"J. Look","year":"2015","journal-title":"Molecular pharmaceutics"},{"issue":"1","key":"pone.0254305.ref029","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.apsb.2017.09.008","article-title":"Substance P-modified human serum albumin nanoparticles loaded with paclitaxel for targeted therapy of glioma","volume":"8","author":"C. Ruan","year":"2018","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"1","key":"pone.0254305.ref030","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0378-5173(03)00134-0","article-title":"Optimization of the preparation process for human serum albumin (HSA) nanoparticles","volume":"257","author":"K. Langer","year":"2003","journal-title":"International Journal of Pharmaceutics"},{"issue":"1","key":"pone.0254305.ref031","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijpharm.2007.06.028","article-title":"Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation","volume":"347","author":"K. Langer","year":"2008","journal-title":"International journal of pharmaceutics"},{"key":"pone.0254305.ref032","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3923\/ajsr.2009.135.145","article-title":"Application of DDQ and p-chloranilic acid for the spectrophotometric estimation of milrinone in pharmaceutical formulations","volume":"2","author":"M. Siddiqui","year":"2009","journal-title":"Asian J Sci Res"},{"issue":"54","key":"pone.0254305.ref033","article-title":"Induction and testing of hypoxia in cell culture","author":"D. Wu","year":"2011","journal-title":"Journal of visualized experiments: JoVE"},{"issue":"1","key":"pone.0254305.ref034","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12012-014-9264-0","article-title":"H2O2 induces myocardial hypertrophy in H9c2 cells: a potential role of Ube3a","volume":"15","author":"R. Song","year":"2015","journal-title":"Cardiovascular toxicology"},{"key":"pone.0254305.ref035","article-title":"A novel milrinone nanoformulation for use in cardiovascular diseases: preparation and in vitro characterization","author":"N. Lomis","year":"2017","journal-title":"Mol Pharm"},{"issue":"3","key":"pone.0254305.ref036","first-page":"271","article-title":"Cardiac regeneration using growth factors: advances and challenges","volume":"107","author":"J.d.S Rebou\u00e7as","year":"2016","journal-title":"Arquivos brasileiros de cardiologia"},{"issue":"8","key":"pone.0254305.ref037","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.nano.2014.06.001","article-title":"Targeted delivery of vascular endothelial growth factor improves stem cell therapy in a rat myocardial infarction model","volume":"10","author":"Y. Tang","year":"2014","journal-title":"Nanomedicine: Nanotechnology, Biology and Medicine"},{"issue":"4","key":"pone.0254305.ref038","doi-asserted-by":"crossref","first-page":"410","DOI":"10.5966\/sctm.2015-0288","article-title":"Strategies and challenges to myocardial replacement therapy","volume":"5","author":"N.T. Feric","year":"2016","journal-title":"Stem cells translational medicine"},{"issue":"3","key":"pone.0254305.ref039","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jsps.2011.04.001","article-title":"Nanoparticles: emerging carriers for drug delivery","volume":"19","author":"S.R. Mudshinge","year":"2011","journal-title":"Saudi pharmaceutical journal"},{"issue":"7","key":"pone.0254305.ref040","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3390\/ph14070697","article-title":"Albumin Nanoparticle Formulation for Heart-Targeted Drug Delivery: In Vivo Assessment of Congestive Heart Failure","volume":"14","author":"N. Lomis","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"3","key":"pone.0254305.ref041","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/sj.cr.7290083","article-title":"The angiotensin II type 1 receptor and receptor-associated proteins","volume":"11","author":"D.F. Guo","year":"2001","journal-title":"Cell Research"},{"key":"pone.0254305.ref042","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fphar.2015.00005","article-title":"Structural determinants for binding to angiotensin converting enzyme 2 (ACE2) and angiotensin receptors 1 and 2","volume":"6","author":"D. Clayton","year":"2015","journal-title":"Front Pharmacol"},{"issue":"5","key":"pone.0254305.ref043","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/17435889.3.5.703","article-title":"Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats","volume":"3","author":"M. Longmire","year":"2008","journal-title":"Nanomedicine (Lond)"},{"issue":"3","key":"pone.0254305.ref044","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1023\/A:1018965121222","article-title":"Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes","volume":"11","author":"H. Harashima","year":"1994","journal-title":"Pharm Res"},{"issue":"13","key":"pone.0254305.ref045","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1016\/j.biomaterials.2011.01.021","article-title":"The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles","volume":"32","author":"K. Xiao","year":"2011","journal-title":"Biomaterials"},{"key":"pone.0254305.ref046","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1146\/annurev.immunol.17.1.593","article-title":"Mechanisms of phagocytosis in macrophages","volume":"17","author":"A. Aderem","year":"1999","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"pone.0254305.ref047","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"D.E. Owens","year":"2006","journal-title":"International journal of pharmaceutics"},{"issue":"13","key":"pone.0254305.ref048","doi-asserted-by":"crossref","first-page":"e015026","DOI":"10.1161\/JAHA.119.015026","article-title":"Extended-Release Oral Milrinone for the Treatment of Heart Failure With Preserved Ejection Fraction","volume":"9","author":"S. Nanayakkara","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"13","key":"pone.0254305.ref049","doi-asserted-by":"crossref","first-page":"e017170","DOI":"10.1161\/JAHA.120.017170","article-title":"Old Drug, New Trick? Oral Milrinone for Heart Failure With Preserved Ejection Fraction","volume":"9","author":"D.N. Silverman","year":"2020","journal-title":"Journal of the American Heart Association"},{"issue":"5","key":"pone.0254305.ref050","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.jtcvs.2014.07.033","article-title":"Sustained release of milrinone delivered via microparticles in a rodent model of myocardial infarction","volume":"148","author":"H. Al Kindi","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"pone.0254305.ref051","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bcpt.12385","article-title":"Milrinone for the Treatment of Acute Heart Failure After Acute Myocardial Infarction: A Systematic Review and Meta\u2010Analysis","volume":"117","author":"X. Tang","year":"2015","journal-title":"Basic & clinical pharmacology & toxicology"},{"issue":"5","key":"pone.0254305.ref052","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10741-017-9632-5","article-title":"Symptom management challenges in heart failure: pharmacotherapy considerations","volume":"22","author":"D. Stewart","year":"2017","journal-title":"Heart failure reviews"},{"issue":"10","key":"pone.0254305.ref053","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2174\/1381612822666160125114900","article-title":"Albumin-based nanodevices as drug carriers","volume":"22","author":"A. Loureiro","year":"2016","journal-title":"Current pharmaceutical design"},{"issue":"2","key":"pone.0254305.ref054","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bbamcr.2014.11.015","article-title":"H9c2 and HL-1 cells demonstrate distinct features of energy metabolism, mitochondrial function and sensitivity to hypoxia-reoxygenation","volume":"1853","author":"A.V. Kuznetsov","year":"2015","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Cell Research"},{"issue":"5","key":"pone.0254305.ref055","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/CIRCRESAHA.110.226803","article-title":"Interrelationship between cardiac hypertrophy, heart failure, and chronic kidney disease: endoplasmic reticulum stress as a mediator of pathogenesis","volume":"108","author":"J.G. Dickhout","year":"2011","journal-title":"Circulation Research"},{"key":"pone.0254305.ref056","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.12659\/MSM.902936","article-title":"Knockdown of MicroRNA-122 Protects H9c2 Cardiomyocytes from Hypoxia-Induced Apoptosis and Promotes Autophagy","volume":"23","author":"Z. Zhang","year":"2017","journal-title":"Medical science monitor: international medical journal of experimental and clinical research"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0254305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T16:14:33Z","timestamp":1673367273000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0254305"}},"subtitle":[],"editor":[{"given":"Michael","family":"Bader","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":56,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0254305","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.07.23.453538","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]}}}